These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26767191)

  • 1. Preclinical toxicology of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for prostate cancer.
    Freytag SO; Zhang Y; Siddiqui F
    Mol Ther Oncolytics; 2015; 2():15006-. PubMed ID: 26767191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer.
    Freytag SO; Barton KN; Zhang Y
    Gene Ther; 2013 Dec; 20(12):1131-9. PubMed ID: 23842593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse.
    Paielli DL; Wing MS; Rogulski KR; Gilbert JD; Kolozsvary A; Kim JH; Hughes J; Schnell M; Thompson T; Freytag SO
    Mol Ther; 2000 Mar; 1(3):263-74. PubMed ID: 10933942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I clinical trial of oncolytic adenovirus mediated suicide and interleukin-12 gene therapy in patients with recurrent localized prostate adenocarcinoma.
    Nyati S; Stricker H; Barton KN; Li P; Elshaikh M; Ali H; Brown SL; Hwang C; Peabody J; Freytag SO; Movsas B; Siddiqui F
    PLoS One; 2023; 18(9):e0291315. PubMed ID: 37713401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer.
    Barton KN; Siddiqui F; Pompa R; Freytag SO; Khan G; Dobrosotskaya I; Ajlouni M; Zhang Y; Cheng J; Movsas B; Kwon D
    Mol Ther Oncolytics; 2021 Mar; 20():94-104. PubMed ID: 33575474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity.
    Barton KN; Paielli D; Zhang Y; Koul S; Brown SL; Lu M; Seely J; Kim JH; Freytag SO
    Mol Ther; 2006 Feb; 13(2):347-56. PubMed ID: 16290236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model.
    Freytag SO; Paielli D; Wing M; Rogulski K; Brown S; Kolozsvary A; Seely J; Barton K; Dragovic A; Kim JH
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):873-85. PubMed ID: 12377341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.
    Freytag SO; Stricker H; Pegg J; Paielli D; Pradhan DG; Peabody J; DePeralta-Venturina M; Xia X; Brown S; Lu M; Kim JH
    Cancer Res; 2003 Nov; 63(21):7497-506. PubMed ID: 14612551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer.
    Freytag SO; Barton KN; Brown SL; Narra V; Zhang Y; Tyson D; Nall C; Lu M; Ajlouni M; Movsas B; Kim JH
    Mol Ther; 2007 Sep; 15(9):1600-6. PubMed ID: 17551507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.
    Freytag SO; Khil M; Stricker H; Peabody J; Menon M; DePeralta-Venturina M; Nafziger D; Pegg J; Paielli D; Brown S; Barton K; Lu M; Aguilar-Cordova E; Kim JH
    Cancer Res; 2002 Sep; 62(17):4968-76. PubMed ID: 12208748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
    Small EJ; Carducci MA; Burke JM; Rodriguez R; Fong L; van Ummersen L; Yu DC; Aimi J; Ando D; Working P; Kirn D; Wilding G
    Mol Ther; 2006 Jul; 14(1):107-17. PubMed ID: 16690359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
    Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
    Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
    Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.
    Herman JR; Adler HL; Aguilar-Cordova E; Rojas-Martinez A; Woo S; Timme TL; Wheeler TM; Thompson TC; Scardino PT
    Hum Gene Ther; 1999 May; 10(7):1239-49. PubMed ID: 10340555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate.
    Barton KN; Stricker H; Brown SL; Elshaikh M; Aref I; Lu M; Pegg J; Zhang Y; Karvelis KC; Siddiqui F; Kim JH; Freytag SO; Movsas B
    Mol Ther; 2008 Oct; 16(10):1761-9. PubMed ID: 18714306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice.
    Timme TL; Hall SJ; Barrios R; Woo SL; Aguilar-Cordova E; Thompson TC
    Cancer Gene Ther; 1998; 5(2):74-82. PubMed ID: 9570298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent antitumor activity of the Ad5/11 chimeric oncolytic adenovirus combined with interleukin-24 for acute myeloid leukemia via induction of apoptosis.
    Wei X; Liu L; Wang G; Li W; Xu K; Qi H; Liu H; Shen J; Li Z; Shao J
    Oncol Rep; 2015 Jan; 33(1):111-8. PubMed ID: 25339149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer.
    Fukuda K; Abei M; Ugai H; Kawashima R; Seo E; Wakayama M; Murata T; Endo S; Hamada H; Hyodo I; Yokoyama KK
    Cancer Gene Ther; 2009 Feb; 16(2):126-36. PubMed ID: 18818710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates.
    Su C; Cao H; Tan S; Huang Y; Jia X; Jiang L; Wang K; Chen Y; Long J; Liu X; Wu M; Wu X; Qian Q
    Toxicol Sci; 2008 Nov; 106(1):242-50. PubMed ID: 18703561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Therapy of Prostate Cancer by Oncolytic Adenovirus Harboring Interleukin 24 and Ionizing Radiation.
    Mao LJ; Kan Y; Li BH; Ma S; Liu Y; Yang DL; Yang C
    Front Oncol; 2020; 10():421. PubMed ID: 32318337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.